The American Journal of Managed Care

Flotufolastat F 18 Injection for Prostate Cancer Added to NCCN Guidelines

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...
Business Wire

Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 LIGHTHOUSE Trial of POSLUMA® (Flotufolastat F 18) Injection in Newly Diagnosed Prostate Cancer

− Oral presentation highlighted at 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting – MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a ...
Business Wire

Blue Earth Diagnostics Announces Addition of POSLUMA® (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer

MONROE TOWNSHIP, NJ, & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, ...
WebMD

How Orgovyx Works for Prostate Cancer

Orgovyx (relugolix) is a medicine used to treat advanced prostate cancer in adults. Advanced prostate cancer means that the cancer has spread outside of the prostate. Advanced cancers have often come ...
KXAN

Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate ...

OXFORD, United Kingdom, May 1, 2025 /PRNewswire/ -- Blue Earth Therapeutics today announced further progress in development of its radiohybrid, lutetium-labelled, PSMA targeted, investigational ...